I
Ian Nivison-Smith
Researcher at St. Vincent's Health System
Publications - 54
Citations - 1301
Ian Nivison-Smith is an academic researcher from St. Vincent's Health System. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 20, co-authored 54 publications receiving 1132 citations. Previous affiliations of Ian Nivison-Smith include Drexel University & St Vincent Hospital.
Papers
More filters
Journal ArticleDOI
Prevalence of malnutrition and 12-month incidence of mortality in two Sydney teaching hospitals.
TL;DR: In this article, the prevalence of malnutrition in two Sydney teaching hospitals using Subjective Global Assessment (SGA), the effect of malnutrition on 12-month mortality and the proportion of patients previously identified to be at nutritional risk were determined.
Journal ArticleDOI
Human gastrointestinal neoplasia-associated myofibroblasts can develop from bone marrow-derived cells following allogeneic stem cell transplantation.
Daniel L. Worthley,Andrew Ruszkiewicz,Ruth Davies,Sarah Moore,Ian Nivison-Smith,Bik To,Peter Browett,R Western,Simon Durrant,Jason C. C. So,Graeme P. Young,Charles G. Mullighan,Peter G Bardy,Michael Michael +13 more
TL;DR: The Australasian Bone Marrow Transplant Recipient Registry was used to identify solid organ neoplasia that developed in female recipients of male allogeneic stem cell transplants and bone marrow‐derived neoplastic cells were identified in the rectal adenoma and in a gastric cancer.
Journal ArticleDOI
The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study
Sylvia Feyler,Henry Miles Prince,Rachel Pearce,K. Towlson,Ian Nivison-Smith,Stephen Schey,John Gibson,N Patton,Kenneth F. Bradstock,David I. Marks,Graham P. Cook +10 more
TL;DR: It is demonstrated that high-dose chemotherapy with autologous stem cell rescue has a substantial role in the management of T-cell lymphoma, and exploration of reduced intensity regimens is warranted.
Journal ArticleDOI
Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.
John Moore,Ian Nivison-Smith,Kim Goh,David D.F. Ma,Kenneth F. Bradstock,Jeff Szer,Simon Durrant,Anthony P. Schwarer,Peter G Bardy,Richard Herrmann,Anthony J. Dodds +10 more
TL;DR: Outcomes for 105 patients undergoing URD transplants for acute myelogenous leukemia and a guide on the subset of patients who may most benefit from an unrelated donor allograft in AML are compared to provide a rationale for a larger prospective study of risk factors in allogeneic transplantation for AML.
Journal ArticleDOI
Intravenous Busulfan Compared With Total Body Irradiation Pretransplant Conditioning for Adults With Acute Lymphoblastic Leukemia
Partow Kebriaei,Claudio Anasetti,Mei-Jie Zhang,Mei-Jie Zhang,Hai-Lin Wang,Ibrahim Aldoss,Marcos de Lima,H. Jean Khoury,Brenda M. Sandmaier,Mary M. Horowitz,Andrew S. Artz,Nelli Bejanyan,Stefan O. Ciurea,Hillard M. Lazarus,Robert Peter Gale,Mark R. Litzow,Christopher Bredeson,Matthew D. Seftel,Michael A. Pulsipher,Jaap-Jan Boelens,Joseph C. Alvarnas,Richard E. Champlin,Stephen J. Forman,Vinod Pullarkat,Daniel J. Weisdorf,David I. Marks,William J. Hogan,Minoo Battiwalla,Edward A. Copelan,Gerhard C. Hildebrandt,Sid Ganguly,Navneet Majhail,Ann E. Woolfrey,Ian Nivison-Smith,Mark P. Hertzberg,Miguel Angel Diaz,Ann A. Jakubowski,Celalettin Ustun,Agnes S. M. Yong,Cesar O. Freytes,Zachariah DeFilipp,Y. Inamoto,Jean-Yves Cahn,Bipin N. Savani,Jean Yared,Ashish Bajel,Ulrike Bacher,Geoffrey L. Uy,David A. Rizzieri,Matthew J. Wieduwilt,Kirk R. Schultz,Michael R. Grunwald,Rammurti T. Kamble,Muna Qayed,Jonathan E. Brammer,Karen K. Ballen,Nandita Khera,Harry C. Schouten,Marc Bierings,Christopher G. Kanakry,William A. Wood,Ayman Saad,Lynn Savoie,Betty K. Hamilton,Mahmoud Aljurf,Ravi Vij,Attaphol Pawarode,Richard F. Olsson,B. Mona Wirk,Amer Beitinjaneh,Sachiko Seo,Jan Cerny,Gorgun Akpek,Maxim Norkin,Taiga Nishihori,Aleksandr Lazaryan,Mitchell Sabloff +76 more
TL;DR: Bu patients were older, with better performance status; took longer to achieve first CR and receive HCT; were treated more recently; and were more likely to receive peripheral blood grafts, antithymocyte globulin, or tyrosine kinase inhibitors.